Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice

Inclusion Criteria: For inclusion in the study patients should fulfil ALL the criteria listed below: 1. A voluntary informed consent form for participation in the study signed by the patient prior to any study-specific procedures 2. Male and female patients of 18-74 years of age 3. Diagnosed type 2 diabetes 4. Therapy with metformin at a stable dose ≤1,500 mg/day for at least 8 weeks before enrolment 5. HbA1c \>7.0% and ≤10% at the Screening Visit 6. C-peptide ≥1.0 ng/ml at the Screening Visit 7. Body mass index ≤45.0 kg/m² at the Screening Visit 8. For women of childbearing potential - use of reliable birth control methods 9. Ability to complete study-specific procedures 10. Ability to complete questionnaires Exclusion Criteria: 1. Type 1 diabetes 2. Diabetic ketoacidosis at Screening 3. AST and/or ALT \> 3 × upper limit of normal at Screening 4. Total serum bilirubin \> 34.19 μmol/l at Screening 5. Decompensated diabetes mellitus (HbA1c \>10% at Screening) 6. Patients with moderate to severe renal impairment (CrCl \<60 ml/min or \<60 ml/min/1.73 m2 at Screening) or terminal renal insufficiency 7. Severe concomitant diseases or severe cardiovascular, renal, hepatic, hematologic, endocrine, mental or rheumatic pathology 8. Malignancy within 5 years before enrolment 9. Acute (including viral and infectious) diseases within 1 month before the Screening Visit. 10. Development of severe acute diseases during the study which significantly affect the benefit/risk ratio for the subject or affecting study efficacy/safety assessment criteria 11. History of acute myocardial infarction or stroke within 6 months before the Screening Visit or during the study. Heart failure (NYHA III-IV) 12. Treatment with drugs affecting glucose homeostasis (e.g., systemic glucocorticosteroids) within 3 months before to the Screening Visit. 13. For women of childbearing potential - a positive pregnancy test or the patient is breast-feeding or planning pregnancy during the study 14. History of Hepatitis B and C or HIV 15. Individual hypersensitivity to any component of the investigational product (dapagliflozin) 16. Treatment with sodium-dependent glucose cotransporter inhibitors (SGLT2) has been administered within 3 months prior to enrolment or is planned during the study. 17. Loop diuretics have been administered for 3 months before the Screening Visit or are planned during the study. 18. Hereditary lactose intolerance, lactase deficiency and glucose-galactose malabsorption 19. The patient is unable to follow study procedures and attend the study centre for scheduled study visits or is going to relocate within the protocol-specific timelines 20. The patient is a subject of other studies within 3 months before enrolment